吉林大学学报(医学版) ›› 2021, Vol. 47 ›› Issue (6): 1502-1509.doi: 10.13481/j.1671-587X.20210621

• 临床研究 • 上一篇    下一篇

基于HMMR在肺腺癌组织中表达水平及其对LUAD患者预后影响的生物信息学分析

李书珍1,曹雅杰1,耿海营1,蔡曾晓瑞1,代春美2,温有锋3,4,李宁1,3,4()   

  1. 1.锦州医科大学基础医学院生物化学与分子生物学教研室,辽宁 锦州 121000
    2.锦州医科大学 药学院,辽宁 锦州 121000
    3.锦州医科大学基础医学院人体解剖学教研室,辽宁 锦州 121000
    4.辽宁省人类表型组学重点研究实验室,辽宁 锦州 121000
  • 收稿日期:2021-04-29 出版日期:2021-11-28 发布日期:2021-12-14
  • 通讯作者: 李宁 E-mail:157026753@qq.com
  • 作者简介:李书珍(1993-),男,河南省驻马店市人,在读硕士研究生,主要从事肺腺癌基础方面的研究。
  • 基金资助:
    国家自然科学基金项目(31400646);辽宁省教育厅高等学校创新人才项目(LR2019028)

Bioinformatics analysis based on expression level of HMMR in lung adenocarcinoma tissue and its impact on prognosis of LUAD patients

Shuzhen LI1,Yajie CAO1,Haiying GENG1,Zengxiaorui CAI1,Chunmei DAI2,Youfeng WEN3,4,Ning LI1,3,4()   

  1. 1.Department of Biochemistry and Molecular Biology,College of Basic Medical Sciences,Jinzhou Medical University,Jinzhou 121000,China
    2.College of Pharmacy,Jinzhou Medical University,Jinzhou 121000,China
    3.Department of Human Anatomy,College of Basic Medical Sciences,Jinzhou Medical University,Jinzhou 121000,China
    4.Liaoning Key Research Laboratory of Human Phenoomic,Jinzhou 121000,China
  • Received:2021-04-29 Online:2021-11-28 Published:2021-12-14
  • Contact: Ning LI E-mail:157026753@qq.com

摘要: 目的

探讨透明质酸介导的细胞游走受体 (HMMR) 在肺腺癌 (LUAD) 组织中的表达及其对LUAD患者预后的影响,阐明HMMR在LUAD发生发展中的作用。

方法

通过基因表达汇编(GEO)、肿瘤基因组图谱(TCGA)和人类蛋白图谱(HPA)数据库评估LUAD组织中HMMR mRNA和蛋白表达水平。采用GEPIA2数据库分析HMMR表达对LUAD患者总生存期(OS)和无病生存期(DFS)的影响,采用TCGA数据库分析HMMR mRNA表达与LUAD患者临床病理参数及预后的关系,采用GSEA富集分析探讨HMMR在LUAD组织中显著富集的通路,采用UALCAN数据库探讨HMMR mRNA表达与TP53基因突变的关系,采用STRING数据库预测HMMR与p53信号通路中蛋白的相互作用。

结果

LUAD组织中HMMR mRNA和蛋白表达水平明显高于正常组织和癌旁组织(P<0.01)。HMMR mRNA表达水平较高的患者OS和DFS更短(P<0.01)。LUAD组织中,HMMR mRNA表达与患者TNM分期、T分期和N分期有关联(P<0.01)。单因素和多因素Cox分析,HMMR mRNA高表达的患者OS更短。GSEA富集分析,细胞周期、同源重组、p53信号通路、膀胱癌、胰腺癌、小细胞肺癌和泛素化介导的蛋白水解等通路显著富集在HMMR高表达显型。

结论

LUAD组织中HMMR表达明显上调,高表达的HMMR mRNA是LUAD患者预后差的独立评价指标。

关键词: 肺腺癌, 透明质酸介导的运动受体, 数据库, 预后

Abstract: Objective

To investigate the expression of hyaluronan-mediated motility receptor (HMMR) in the lung adenocarcinoma (LUAD) tissue and its impact on the prognosis of the LUAD patients, and to elucidate the role of HMMR in the occurrence and development of LUAD.

Methods

The expression levels HMMR mRNA and protein in the LUAD tissue were assessed by Gene Expression Omnibus (GEO), the Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA). The effect of HMMR expression on the overall survival (OS) and disease-free survival (DFS) of the LUAD patients was analyzed by using the GEPIA2 database. The relationships between HMMR mRNA expression and the clinicopathological parameters and prognosis of the LUAD patients were analyzed by using the TCGA database. The GSEA enrichment analysis was used to explore the pathways significantly enriched for HMMR in the LUAD tissue. The relationship between HMMR mRNA expression and TP53 gene mutations was probed by using the UALCAN database, and the interaction between HMMR and the proteins in the p53 signaling pathway was predicted by the Search Tool for Recurring Instances of Neighbouring Genes (STRING) database.

Results

The expression levels of HMMR mRNA and protein in LUAD tissue were significantly higher than those in normal and adjacent tissues (P<0.01). The patients with higher HMMR mRNA expression had shorter OS and DFS(P<0.01). In LUAD tissue, the HMMR mRNA expression was associated with the patients’ TNM stage,T stage, and N stage (P<0.01).The univariate and multivariate Cox analysis results showed that the OS of the patients with high HMMR mRNA expression was shorter. The GSEA enrichment analysis results showed that cell cycle, homologous recombination, p53 signaling pathway, bladder cancer, pancreatic cancer, small cell lung cancer, and ubiquitin-mediated proteolysis pathways were significantly enriched in the high expression phenotype of HMMR.

Conclusion

The expression of HMMR in LUAD tissue is significantly up-regulated,and the highly expressed HMMR mRNA is an independent evaluation indicator of poor prognosis in the LUAD patients.

Key words: lung adenocarcinoma, hyaluronan-mediated motility receptor, database, prognosis

中图分类号: 

  • R734.2